Artificial intelligence (AI) is amplifying the pace of drug development, allowing developers to attack otherwise intractable problems and achieve results in weeks. Previously, results may have been impossible within any time frame.
University of Connecticut professor of molecular and cell biology James Cole is working on identifying new therapeutics for COVID-19. Through a collaboration with Atomwise, Cole is one of the 15 researchers looking at different coronavirus protein targets for COVID-19 treatment.
The University of Kentucky announced a research collaboration with Atomwise, an industry leader in using artificial intelligence (AI) for small molecule discovery, to explore potential COVID-19 therapies.
AI-based drug discovery specialist Atomwise has revealed details of 15 research collaborations seeking… To continue reading The Pharma Letter please login, subscribe or claim a 7 day free trial subscription and access exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space.
There are presently 15 research collaborations underway to enable academic researchers to discover novel therapies for the COVID-19 pandemic and those in the future using advanced artificial intelligence (AI) technology developed by Atomwise Inc. (San Francisco, CA, USA).